Clinical trial · Observational
Navigating the Clinical Research Process for Lymphoma
Gaining Insights Into Patient Involvement Patterns and Trends in Participation in Lymphoma Clinical Trials
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participation in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This trial will admit a wide range of data on the clinical trial experience of lymphoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future lymphoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of patients who decide to enroll in a lymphoma clinical research.
- timeFrame
- 3 months
- measure
- Number of lymphoma study participants who remain in clinical study until completion.
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of lymphoma * Participant must be 18 years of age or older * Participant must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study. Exclusion Criteria: * Pregnant or lactating woman * Participant is actively receiving study therapy in another * Inability to provide written informed consent
References
Publications (3)
- BACKGROUNDHe X, Xu P, Wang X, Jiang S, Gong D, Wu N. The association of gene rearrangement and lymphoma diagnosis: A prospective observational study. Medicine (Baltimore). 2020 Jun 12;99(24):e20733. doi: 10.1097/MD.0000000000020733. PMID 32541525
- BACKGROUNDDhir V, Maganti M, Rozenberg D, Kukreti V, Kuruvilla J, Crump M, Prica A. Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e792-e803. doi: 10.1016/j.clml.2022.04.011. Epub 2022 Apr 29. PMID 35650009
- BACKGROUNDTanaka R, Kaburaki T, Taoka K, Karakawa A, Tsuji H, Nishikawa M, Yatomi Y, Shinozaki-Ushiku A, Ushiku T, Araki F. More Accurate Diagnosis of Vitreoretinal Lymphoma Using a Combination of Diagnostic Test Results: A Prospective Observational Study. Ocul Immunol Inflamm. 2022 Aug;30(6):1354-1360. doi: 10.1080/09273948.2021.1873394. Epub 2021 Apr 1. PMID 33793360